Scarica l'app Stockscreener
32.80
1.97%
-0.66
Dopo l'orario di chiusura:
32.80
Precedente Chiudi:
$33.46
Aprire:
$33.28
Volume 24 ore:
1.81M
Relative Volume:
1.46
Capitalizzazione di mercato:
$5.90B
Reddito:
$520.18M
Utile/perdita netta:
$-348.13M
Rapporto P/E:
-17.08
EPS:
-1.92
Flusso di cassa netto:
$-176.18M
1 W Prestazione:
+4.86%
1M Prestazione:
-13.55%
6M Prestazione:
-23.88%
1 anno Prestazione:
-32.83%
Intervallo 1D:
$31.68
$33.30
Intervallo di 1 settimana:
$31.23
$35.11
Portata 52W:
$29.27
$60.87
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Nome
Legend Biotech Corp Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta LEGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
32.80 | 5.90B | 520.18M | -348.13M | -176.18M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-06-17 | Iniziato | Truist | Buy |
| 2024-05-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-05-23 | Iniziato | Deutsche Bank | Buy |
| 2024-04-17 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | Raymond James | Outperform |
| 2023-12-19 | Iniziato | Scotiabank | Sector Perform |
| 2023-11-06 | Iniziato | Goldman | Buy |
| 2023-05-25 | Iniziato | William Blair | Mkt Perform |
| 2023-05-22 | Iniziato | Daiwa Securities | Buy |
| 2023-03-29 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-11-02 | Iniziato | Evercore ISI | Outperform |
| 2022-11-01 | Iniziato | Cowen | Outperform |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-03-15 | Iniziato | Barclays | Overweight |
| 2022-01-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-18 | Iniziato | BTIG Research | Buy |
| 2020-07-01 | Iniziato | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Legend Biotech Corp Adr Borsa (LEGN) Ultime notizie
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last? - Yahoo Finance
Piper Sandler bullish on biotech stocks amid market swings By Investing.com - Investing.com South Africa
Piper Sandler bullish on biotech stocks amid market swings - Investing.com
TD Cowen maintains Legend Biotech $62 target on strong Q1 outlook - Investing.com India
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? - Yahoo Finance
H.C. Wainwright maintains Legend Biotech stock Buy rating, $75 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Legend Biotech stock Buy rating, $75 target - Investing.com
Legend Biotech stock hits 52-week low at $30.16 amid market challenges By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $30.16 amid market challenges - Investing.com
Compared to Estimates, Legend Biotech (LEGN) Q4 Earnings: A Look at Key Metrics - MSN
Legend Biotech’s SWOT analysis: carvykti’s strong efficacy drives stock outlook - Investing.com
Piper Sandler maintains Overweight on Legend Biotech, $78 target By Investing.com - Investing.com South Africa
RBC Capital maintains Outperform rating on Legend Biotech shares - Investing.com
RBC Capital maintains Outperform rating on Legend Biotech shares By Investing.com - Investing.com South Africa
BMO Capital maintains Legend Biotech at Outperform with $90 target - Investing.com
BMO Capital maintains Legend Biotech at Outperform with $90 target By Investing.com - Investing.com UK
Piper Sandler maintains Overweight on Legend Biotech, $78 target - Investing.com India
Legend Biotech stock price target raised to $75 at H.C. Wainwright - Investing.com India
Legend Biotech reports Q4 earnings beat, revenue tops estimates By Investing.com - Investing.com South Africa
Legend Biotech reports Q4 earnings beat, revenue tops estimates - Investing.com India
Earnings call transcript: Legend Biotech Q4 2024 sees strong CARVICTI growth By Investing.com - Investing.com South Africa
Earnings call transcript: Legend Biotech Q4 2024 sees strong CARVICTI growth - Investing.com India
Legend Biotech CorpADR to Host Earnings Call - ACCESS Newswire
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? - Yahoo Finance
Market Momentum: Aptargroup Inc (ATR) Registers a 0.07 Increase, Closing at 143.28 - The Dwinnex
Legend Biotech Corp ADR (LEGN) rating initates by Redburn Atlantic - Knox Daily
A Guide To The Risks Of Investing In Worksport Ltd (WKSP) - Knox Daily
Legend Biotech Corp ADR (LEGN) stock analysis: A comprehensive overview - US Post News
Beyond Meat Inc (BYND)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Deeper Dive: Understanding Legend Biotech Corp ADR (LEGN) Through its Various Ratios - The Dwinnex
Legend Biotech Corp ADR (LEGN) looking to reclaim success with recent performance - SETE News
CIMG Inc (IMG)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Ratio Analysis: Unpacking XPLR Infrastructure LP (XIFR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Ratios in Focus: Analyzing Aurora Mobile Ltd ADR (JG)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Analyze Legend Biotech Corp ADR (NASDAQ: LEGN) Before Investing. - Stocks Register
Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid competition - Investing.com India
Barclays lifts Johnson & Johnson stock target to $166 - Investing.com
Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength? - Yahoo Finance
Legend Biotech stock target cut to $91 by Jefferies - Investing.com South Africa
Legend Biotech keeps stock at Buy rating on strong position - Investing.com India
When will lagging health care stocks return to healthy growth? - The Globe and Mail
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential - Investing.com India
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential By Investing.com - Investing.com South Africa
With BIOSECURE in limbo, should BeiGene or Legend sell itself in 2025? Analysts weigh in - Fierce Pharma
Legend Biotech's SWOT analysis: carvykti sales boost stock amid competition - Investing.com India
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook By Investing.com - Investing.com South Africa
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook - Investing.com India
Legend Biotech Corp Adr Azioni (LEGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):